Clinical Observation on Toxin-Resolving Blood-Cooling Formula Combined with Western Medicine for 64 Cases of Hepatitis B Related Acute-on-Chronic Liver Failure

LIU Huimin; WANG Xianbo; HOU Yixin; GAO Fangyuan; SUN Fengxia; JIANG Yuyong; YANG Zhiyun; DU Hongbo; WANG Xiaojing; ZHOU Guiqin; YANG Yuying; WANG Rongbing

doi:10.13288/j.11-2166/r.2013.21.027

您当前的位置：

首页 >

文章列表页 >

Clinical Observation on Toxin-Resolving Blood-Cooling Formula Combined with Western Medicine for 64 Cases of Hepatitis B Related Acute-on-Chronic Liver Failure

更新时间：2021-11-17

- Clinical Observation on Toxin-Resolving Blood-Cooling Formula Combined with Western Medicine for 64 Cases of Hepatitis B Related Acute-on-Chronic Liver Failure
- Journal of Traditional Chinese Medicine Vol. 54, Issue 21, Pages: 1829-1833(2013)
- 作者机构：
  
  首都医科大学附属北京地坛医院中西医结合中心
- 作者简介：
- 基金信息：
- DOI：10.13288/j.11-2166/r.2013.21.027
  CLC： R512.62;R575.3
- Published：2013
- 稿件说明：
移动端阅览
[1]刘慧敏,王宪波,侯艺鑫,高方媛,孙凤霞,江宇泳,杨志云,杜宏波,王晓静,周桂琴,杨玉英,王融冰.解毒凉血方联合西药治疗乙型肝炎慢加急性肝衰竭患者64例临床观察[J].中医杂志,2013,54(21):1829-1833.

LIU Huimin, WANG Xianbo, HOU Yixin, et al. Clinical Observation on Toxin-Resolving Blood-Cooling Formula Combined with Western Medicine for 64 Cases of Hepatitis B Related Acute-on-Chronic Liver Failure[J]. Journal of Traditional Chinese Medicine2013, 54(21): 1829-1833.
[1]刘慧敏,王宪波,侯艺鑫,高方媛,孙凤霞,江宇泳,杨志云,杜宏波,王晓静,周桂琴,杨玉英,王融冰.解毒凉血方联合西药治疗乙型肝炎慢加急性肝衰竭患者64例临床观察[J].中医杂志,2013,54(21):1829-1833. DOI： 10.13288/j.11-2166/r.2013.21.027.

LIU Huimin, WANG Xianbo, HOU Yixin, et al. Clinical Observation on Toxin-Resolving Blood-Cooling Formula Combined with Western Medicine for 64 Cases of Hepatitis B Related Acute-on-Chronic Liver Failure[J]. Journal of Traditional Chinese Medicine2013, 54(21): 1829-1833. DOI： 10.13288/j.11-2166/r.2013.21.027.

摘要

目的观察解毒凉血方联合西药治疗乙型肝炎慢加急性肝衰竭（ACLF）热毒瘀结证的临床疗效

并探讨其有效患者群。方法将105例热毒瘀结证乙型肝炎ACLF患者随机分为中西医结合组64例与西医治疗组41例。西医治疗组给予西医内科综合治疗

中西医结合组在西医治疗的基础上加用解毒凉血方

共治疗8周

随访40周。比较两组治疗后第8、48周时的临床疗效

观察两组患者治疗第0、2、4、6、8、12、24、48周时中医证候积分及终末期肝病模型（MELD）评分

并根据MELD评分探讨有效患者群。结果治疗8周时

中西医结合组和西医治疗组总有效率分别为75.00%和51.22%

病死率分别为15.63%和34.15%

两组总有效率和病死率比较差异均有统计学意义（P<0.05）;随访至48周时

中西医结合组和西医治疗组总有效率分别为70.31%和51.22%

病死率分别为21.88%和39.02%

两组总有效率和病死率比较差异均有统计学意义（P<0.05）。中西医结合组治疗后及随访时各时间点中医证候评分、MELD评分均较治疗开始时下降（P<0.05）

西医治疗组治疗第8周及随访各时间点中医证候评分、治疗第4周后及随访各时间点MELD评分较治疗开始时下降（P<0.05）;组间比较

中西医结合组治疗后第2～12周中医证候评分及第2、4、6、8周MELD评分均较同时间点西医治疗组降低（P<0.05）。MELD评分在22.6～29.9分的患者

中西医结合组的病死率为23.81%

西医治疗组为58.82%

两组比较差异有统计学意义（P<0.05）。结论解毒凉血方联合西医综合治疗能够提高乙型肝炎ACLF的临床疗效

降低MELD评分介于22.6～29.9分的患者的病死率。

Abstract

Objective To observe the therapeutic effect of Toxin-Resolving Blood-Cooling Formula（TRBCF）combined with western medicine for hepatitis B related acute-on-chronic liver failure（HB-ACLF）with heat-toxin stasis bind pattern and research its effective patient population.Methods Totally 105 HB-ACLF patients with heat-toxin stasis bind pattern were randomized into the integrative medicine group of 64 cases and western medicine group of 41 cases.The western medicine group was given western comprehensive treatment.The integrative medicine group was added with TRBCF.The treatment lasted for 8 weeks and the follow-up lasted for 40 weeks.The clinical efficacy in both groups was compared in the 8th and 48th week.The TCM pattern scores and model for end-stage liver disease（MELD）scores in both groups were observed in the 0

2nd

4th

6th

8th

12th

24th and 48th week.The effective patient population was analyzed according to MELD score.Results After 8-week treatment

the total effective rate of the integrative medicine group and western medicine group was 75.00% and 51.22%respectively and the mortality rate was 15.63% and 34.15%respectively

with a significant difference between groups（P<0.05）.In the 48th week

the total effective rate of the integrative medicine group and western medicine group was70.31% and 51.22% respectively and the mortality rate was 21.88% and 39.02% respectively

with a significant difference between groups（P<0.05）.The TCM pattern score and MELD score at each time point of treatment and follow-up was significantly decreased in the integrative medicine group（P<0.05）.The TCM pattern score was significantly decreased in the8th week and at each time point of follow-up and MELD score was significantly deceased in the 6th and 8th week and at each time point of follow-up in the western medicine group（P<0.05）.Comparing with the western medicine group

the TCM pattern score was significantly decreased from the 2nd to 12th week and MELD score was significantly deceased in the 2nd

4th

6th and 8th week in the integrative medicine group（P<0.05）.The mortality rate of patients whose MELD score ranging from 22.6 to 29.9was 23.81% and 58.82% in the integrative medicine group and western medicine group respectively（P<0.05）.Conclusion The combo therapy of TRBCF and western medicine can increase effective rate and reduce mortality rate of HB-ACLF patients whose MELD score ranging from 22.6 to 29.9.

关键词

Keywords

references

查看原文

Views

307

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Effect of Yiqi Huoxue Jiedu Huatan Formula on Liver Fibrosis Caused by Chronic Hepatitis B:A Clinical Report of 49 Cases

The Philosophy and Practical Pathway of "Dao （道）-Shen （神）-Formula" in Traditional Chinese Medicine

LI Guolie's Experience in Treating Orthostatic Hypotension from the Perspective of "Raising the Clear and Directing the Turbid Downward"

Efficacy and Economic Evaluation of Weishi Qingjin Formula （苇石清金方）in the Treatment of Adult Community-Acquired Pneumonia with Phlegm-Heat Obstructing the Lung Syndrome：A Multicenter Retrospective Real-World Cohort Study

Effect of Xiaoqinglong Decoction （小青龙汤） on Th2 Immune Responses and Nasal Mucosal TSLP/OX40L Pathway in Allergic Rhinitis Model Rats

Related Author

QI Jing

XU Chunjun

WEN Qingxiang

Related Institution

Beijing Traditional Chinese Medicine Hospital,Capital Medical University

Address：No.16, Nanxiao street, Dongzhimen, Dongcheng District, Beijing Postal code：100700
Tel：010-64035632 Email：jtcmcn@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19 京公网安备11010102007558号
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰